Terms: = Prostate cancer AND CgA AND Diagnosis
27 results:
1. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
2. [Clinicopathological Features of Primary Small Cell Neuroendocrine Carcinoma of the Bladder].
Gu YM; Liang XL; Zhang YG; Zhao HY; Jin ML; Li X; Lu J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2023 Jun; 45(3):429-435. PubMed ID: 37407530
[TBL] [Abstract] [Full Text] [Related]
3. Neuroendocrine cells in prostate cancer correlate with poor outcomes: a systematic review and meta-analysis.
Kannan A; Clouston D; Frydenberg M; Ilic D; Karim MN; Evans SM; Toivanen R; Risbridger GP; Taylor RA
BJU Int; 2022 Oct; 130(4):420-433. PubMed ID: 34784097
[TBL] [Abstract] [Full Text] [Related]
4. Frailty and diabetes status in older patients with cancer: impact on mortality in the ANCRAGE cohort.
Liuu E; Saulnier PJ; Gand E; Ragot S; Valero S; Jamet A; Hadjadj S; Paccalin M
Aging Clin Exp Res; 2020 Sep; 32(9):1809-1819. PubMed ID: 31898171
[TBL] [Abstract] [Full Text] [Related]
5. Non-functional paraganglioma of urinary bladder managed by transurethral resection.
Zhang B; Fu Z; Liu L; Qiao B; Liu C
Int Braz J Urol; 2019; 45(5):910-915. PubMed ID: 31038858
[TBL] [Abstract] [Full Text] [Related]
6. [Demographic change: Changes in society and medicine and developmental trends in geriatrics].
Kolb GF; Weißbach L
Urologe A; 2015 Dec; 54(12):1701-9. PubMed ID: 26704273
[TBL] [Abstract] [Full Text] [Related]
7. prostate cancer in Elderly Men: Screening, Active Surveillance, and Definitive Therapy.
Roussel B; Ouellet GM; Mohile SG; Dale W
Clin Geriatr Med; 2015 Nov; 31(4):615-29. PubMed ID: 26476120
[TBL] [Abstract] [Full Text] [Related]
8. Tissue Chromogranin A Expression during prostate cancer Progression: Prediction of Chemosensitivity.
Mitsui Y; Arichi N; Hiraki M; Harada Y; Yasumoto H; Shiina H
Urol J; 2015 Jul; 12(3):2165-72. PubMed ID: 26135933
[TBL] [Abstract] [Full Text] [Related]
9. [Metastases to the breast from non-mammary malignancies: a clinicopathologic study of 28 cases].
Zhou S; Yu B; Cheng Y; Xu X; Shui R; Bi R; Lu H; Tu X; Yang W
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):231-5. PubMed ID: 24915812
[TBL] [Abstract] [Full Text] [Related]
10. Chromogranin A--serum marker for prostate cancer.
Khan MO; Ather MH
J Pak Med Assoc; 2011 Jan; 61(1):108-11. PubMed ID: 22368921
[TBL] [Abstract] [Full Text] [Related]
11. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract] [Full Text] [Related]
12. Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.
Ather MH; Abbas F; Faruqui N; Israr M; Pervez S
BMC Urol; 2008 Dec; 8():21. PubMed ID: 19115997
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
[TBL] [Abstract] [Full Text] [Related]
14. [Non-Hodgkin's lymphoma of the prostate: a report of 2 cases and review of the literature].
Shen XJ; Zheng XG; Zhou XJ; Zhou HB
Zhonghua Nan Ke Xue; 2007 Oct; 13(10):895-8. PubMed ID: 17977320
[TBL] [Abstract] [Full Text] [Related]
15. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract] [Full Text] [Related]
16. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract] [Full Text] [Related]
17. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
Yamada Y; Nakamura K; Aoki S; Taki T; Naruse K; Matsubara H; Tobiume M; Zennami K; Katsuda R; Honda N
BJU Int; 2007 Jan; 99(1):189-95. PubMed ID: 17034504
[TBL] [Abstract] [Full Text] [Related]
18. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract] [Full Text] [Related]
19. [Plasma chromogranin-A (cga)--a potential marker for diagnosis, monitoring and management of prostate cancer patients].
Leibovitch I; Pinthus Y; Sella BA; Ramon J
Harefuah; 2006 Jan; 145(1):25-9, 78. PubMed ID: 16450720
[TBL] [Abstract] [Full Text] [Related]
20. Chromogranin A expression in familial versus sporadic prostate cancer.
Sciarra A; Monti S; Gentile V; Salciccia S; Autran Gòmez AM; Pannunzi LP; Di Silverio F
Urology; 2005 Nov; 66(5):1010-4. PubMed ID: 16286114
[TBL] [Abstract] [Full Text] [Related]
[Next]
